International
Farewell to the Spanish Observatory of Medicinal Cannabis

After a decade of fighting for fairer policies for patients who need access to cannabis in Spain, Carola Pérez, founder and president of Spanish Observatory of Medicinal Cannabis (OECM) announced that it is throwing in the towel and dissolving the association, due to the systematic and growing difficulties in defending patients and the plant in general in the country's political context.
It was through her personal LinkedIn page that Carola Pérez informed the community, in a tone of relief: “It has been 10 years of fighting against the Spanish government. We have worked hard, we have made a great effort. We were born with death announced and it is time to rest. We cannot do any more with this cruel and inhumane Ministry of Health. We have taken a big step, considering the PSOE’s refusal to provide any kind of relief to patients (except for Sativex® and Epidiolex®). It’s not enough for us but, to be honest, we can’t achieve more at the moment.”
Just when things seem to be moving forward in Spain in terms of medicinal cannabis, the news took a large part of the community by surprise. But speaking to CannaReporter® during Spannabis in Barcelona, Carola explained that they decided to close the Observatory at this time “because now that the royal decree has been finalized and will be published soon, we have achieved our goal”. However, she once again expressed her frustration, explaining that “maybe we haven’t achieved the things we would have liked to do to satisfy patients, but, as with other countries, you get what you can. It’s been an incredible 10 years and now it’s time to rest.”
According to the website, the Spanish Observatory of Medicinal Cannabis was created in 2015 with the aim of “promoting, coordinating and implementing activities and projects that promote knowledge of the properties and medicinal uses of cannabis and its derivatives”, expanding its scope of action to provide advice and information about the plant, based on scientific evidence, to any public or private institution, as well as to civil society. It was formed by associations of patients, researchers and doctors, among them Professor Manuel Guzmán, a researcher at the Biochemistry and Molecular Biology at the Complutense University of Madrid, who has been one of the most active voices in cannabinoid-related science in Spain.
The strange case of Spain
Spain is a peculiar case in the panorama of medicinal cannabis – and cannabis in general. Despite the clear openness of society towards the plant, the historical negligence towards home cultivation (the law allows the cultivation of a small, unspecified quantity of plants in a private environment) and being the country where cannabis clubs have proliferated from Barcelona, even though they are not legal, the Spanish Ministry of Health has not kept up with developments in the rest of the world, taking a long time to publish specific regulations for the use of cannabis for medicinal purposes. It was only last year that the newly appointed Minister of Health, Mónica Garcia, announced the new legal framework, in accordance with the recommendations of the Health Committee of the Congress, and presented it for public consultation. After receiving the reactions (largely ignored) and without any changes to the draft by the European Union, the “Royal Decree regulating the dispensation of master formulas of standardized cannabis products with therapeutic purposes” should be ratified by the summer.
How CannaReporter® reported at the time, the reactions of patients and associations – including the OECM – were also of great frustration, since the proposal denies patients access to flowers and oils, “allowing cannabis-based medicines to be prescribed in the form of 'master formulas', made from standardized extracts or preparations”. In other words: patients can only access Epidiolex® and Sativex®, two medicines sold only in hospital pharmacies, at much higher prices than flowers or other types of preparations – when in most cases they need other compositions of cannabinoids and terpenes, more appropriate for their particular illness or condition.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

The PDF link is broken, it has a strange Chrome extension!
Thanks for the heads up, we've already fixed the link.
Thanks for the warning, we've fixed the link.
In the section “The Strange Case of Spain”, there is a link error for the PDF!